Analysts expect KALA BIO, Inc. to report revenue of 0.00 for Q2 25, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 25, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||||||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.97 M | |||||||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.41 M | |||||||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.69 M |
Analysts expect KALA BIO, Inc. to report earnings per share of -49.42 for Q3 25, against a range of -51.80 to -47.04. The most recent reported quarter, Q2 25, came in at -85.50, a 3.8% miss against the -82.38 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -96.50 | -87.00 | -70.50 | -85.50 | - | - | - | - | - | - | - | - | ||||||||||||||
| High Estimate | -118.62 | -98.87 | -86.88 | -76.17 | -47.04 | -13.96 | -8.73 | -5.51 | -5.30 | -5.41 | -9.25 | -5.66 | ||||||||||||||
| Low Estimate | -135.96 | -114.13 | -104.80 | -88.59 | -51.80 | -16.86 | -9.45 | -5.85 | -5.88 | -6.17 | -10.21 | -6.46 | ||||||||||||||
| Consensus Estimate | -127.29 | -106.50 | -95.84 | -82.38 | -49.42 | -15.41 | -9.09 | -5.68 | -5.59 | -5.79 | -9.73 | -6.06 |